| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
We measured expression of LOX-1 protein in cell-line and specimen of head and neck carcinoma. We compared expression of LOX-1 protein malignant tumor with normal tissue in head and neck legion. Moreover, we examined expression of LOX-1 protein in real tissue of head and neck carcinoma by anti-LOX-1 antibody. We acquired results as follows:
LOX-1 protein expressed in each head and neck organ, especially in oropharynx and tongue, with certain quantity. LOX-1 protein prominent expressed in hypopharyngeal and esophageal carcinoma add to oropharyngeal and tongue cancer. Expression of LOX-1 in malignant tumor was significant higher than normal tissue. Expression of LOX-1 protein in recurrent tumor increased clearly compared with untreated tumor. It was clarified that there is not difference of quantity of expression LOX-1 and CyclinD1. Prognosis of the patient having head and neck carcinoma with high expression of LOX-1 protein was better than those without expression of LOX-1 protein.
|
